MDG1011 is a therapy which aims to improve outcomes for in patients with high-risk blood cancers

Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer

The Consort group includes many initiatives to improve reporting of results from randomised controlled trials (RCTs). The original […]

Randomised controlled trials are the reference standard among study designs to investigate the benefits of interventions. These trials […]

A research team has shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus […]

Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic […]

The government’s announcement in March that it plans to ban possession of nitrous oxide by making it a […]

Calls for the government to produce better, clearer, and independently audited NHS and social care workforce plans have […]

The Institute of Health Promotion and Education has concerns about the recent public health grant allocations in terms […]